A monoclonal antibody (mAb) that binds to a transient intermediate may act as a catalyst for the corresponding reaction; here we show this principle can extend on a macro molecular scale to the induction of mutant-like oligomerization in a wild-type protein. Using the common pathogenic E342K (Z) variant of α1-antitrypsin as antigen-whose native state is susceptible to the formation of a proto-oligomeric intermediate-we have produced a mAb (5E3) that increases the rate of oligomerization of the wild-type (M) variant. Employing ELISA, gel shift, thermal stability and FRET time-course experiments, we show that mAb5E3 does not bind to the native state of α1-antitrypsin, but recognizes a cryptic epitope in the vicinity of the post-helix A loop a...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
AbstractThe wild-type form of plasminogen activator inhibitor type-2 (PAI-2) and the pathogenic Z-mu...
Serpins are important regulators of proteolytic pathways with an antiprotease activity that involves...
Serpins are important regulators of proteolytic pathways with an anti-protease activity that involve...
The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associa...
The common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that are reta...
AbstractThe common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that ...
The common severe Z mutation (E342K) of alpha(1)-antitrypsin forms intracellular polymers that are a...
AbstractThe human serine protease inhibitor (serpin) α-1 antitrypsin (α1-AT) protects tissues from p...
The serpinopathies result from the ordered polymerization of mutants of members of the serine protei...
The formation of ordered Z (Glu342Lys) α1‐antitrypsin polymers in hepatocytes is central to liver di...
Mutant Z α1-antitrypsin (E342K) accumulates as polymers within the endoplasmic reticulum (ER) of hep...
Protein misfolding is associated with a range of diseases and occurs when a protein meanders from it...
The serpinopathies are among a diverse set of conformational diseases that involve the aberrant self...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
AbstractThe wild-type form of plasminogen activator inhibitor type-2 (PAI-2) and the pathogenic Z-mu...
Serpins are important regulators of proteolytic pathways with an antiprotease activity that involves...
Serpins are important regulators of proteolytic pathways with an anti-protease activity that involve...
The common severe Z mutation (E342K) of α1-antitrypsin forms intracellular polymers that are associa...
The common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that are reta...
AbstractThe common Z mutant (Glu342Lys) of α1-antitrypsin results in the formation of polymers that ...
The common severe Z mutation (E342K) of alpha(1)-antitrypsin forms intracellular polymers that are a...
AbstractThe human serine protease inhibitor (serpin) α-1 antitrypsin (α1-AT) protects tissues from p...
The serpinopathies result from the ordered polymerization of mutants of members of the serine protei...
The formation of ordered Z (Glu342Lys) α1‐antitrypsin polymers in hepatocytes is central to liver di...
Mutant Z α1-antitrypsin (E342K) accumulates as polymers within the endoplasmic reticulum (ER) of hep...
Protein misfolding is associated with a range of diseases and occurs when a protein meanders from it...
The serpinopathies are among a diverse set of conformational diseases that involve the aberrant self...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
α1-Antitrypsin is primarily synthesised in the liver, circulates to the lung and protects pulmonary ...
AbstractThe wild-type form of plasminogen activator inhibitor type-2 (PAI-2) and the pathogenic Z-mu...